Peter, for the first time since the beginning of civilisation - the biotech index is following the broad markets. Now why is that? Could it be accounting problems? Personally I wouldn't touch this sector until we see two things; one, capitulation ... two, J&J buying up the juniors ten at a time. I'm thinking consolidation in this sector is the inevitable bottom.
Regards,
Frank P.